Triumvira Immunologics Appoints Chief Medical Officer

AUSTIN, Texas & HAMILTON, Ontario–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it has appointed Deyaa Adib, M.D., to serve as the company’s Chief Medical Officer, effective immediately. Dr. Adib will report to President and CEO Dr. Paul Lammers and will succeed Dr. Sabine Chlosta.

As a seasoned industry leader, Dr. Adib has over 24 years of medical oncology experience in the biotechnology and pharmaceutical industries, including seven successful registrations across solid tumor and hematologic malignancy indications. He previously served as acting chief medical officer at Rain Therapeutics, where he built the oncology portfolio leading to a successful IPO, and vice president of late-stage development at Blueprint Medicines advancing the development of avapritinib approved for gastrointestinal stromal tumor and advanced systemic mastocytosis. Dr. Adib also served as global therapeutics head for solid tumors at Baxalta, advancing the development of imalumab in colorectal cancer, non-small cell lung cancer (NSCLC), and ovarian cancer, and licensing nanoliposomal irinotecan that was subsequently approved for pancreatic cancer. In this role, he also led the efforts to secure licensing and development of a CD-19 target with Precision Biosciences in B cell malignancies and PD1, LAG3, TIM3 solid tumor targets with Symphogen, a Servier company. He also served as head of hematologic malignancies at ARIAD Pharmaceuticals (now part of Takeda) leading the global clinical program for ponatinib dose-finding and line extension in chronic myeloid leukemia.

TACTIC-2 Marks First In-Human Use of TAC-T Cell Therapy

Phase 1/2 clinical trial will evaluate TAC01-HER2, Triumvira’s lead candidate, in patients with HER2-overexpressing solid tumors
First patient dosed at MD Anderson Cancer Center in Houston, Texas
AUSTIN, Texas & HAMILTON, Ontario–Triumvira Immunologics (Triumvira) today announced that the first patient has been dosed as part of the TACTIC-2 trial evaluating the company’s lead candidate, TAC01-HER2, an autologous T cell therapy for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors. Triumvira, a clinical-stage company, is developing novel, targeted autologous, and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid and liquid tumors. The company’s proprietary T cell Antigen Coupler (TAC) platform technology activates natural T cell functions differently from other cell therapies such as Chimeric Antigen Receptor T cell (CAR-T) and engineered T cell receptor therapies.

Appointment of Chief Financial Officer and Promotions

AUSTIN, Texas & HAMILTON, Ontario–Triumvira Immunologics (“Triumvira” or the “Company”), a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Teresa McRoberts as Chief Financial Officer. The Company also announced the promotion of Andreas Bader, Ph.D. to Chief Scientific Officer and Jon Irvin to Senior Vice President of Finance.

“Both Andy and Jon have been integral to the rapid growth of Triumvira and we are also excited to announce their promotions today. Andy has played an instrumental role in shaping our scientific strategy with a track record of taking research programs from the discovery stage into the clinic, and Jon has played a critical role in guiding our financial strategy to date as we’ve quickly scaled up our company.”

Series A Financing Round Success

LEVERKUSEN, Germany & AUSTIN, Texas–Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD $55 million Series A financing round. The financing was co-led by Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures. Additional investors include Oceanpine Capital and Viva Biotech Holdings, and existing investors include Bloom Burton & Co. and the Centre for Commercialization of Cancer Immunotherapy (C3i).

Triumvira is committed to developing novel T-cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T-cell receptor (TCR) therapies. This financing will enable Triumvira to advance multiple autologous and allogeneic programs into the clinic for solid tumors and hematologic malignancies.

Patent Announcements

AUSTIN, Texas & HAMILTON, Ontario–Triumvira Immunologics Inc. (Triumvira), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced the issuance of key claims in U.S. Patent No. 10640562 entitled “T cell-antigen coupler with various construct optimizations.” The newly allowed TAC-CD19 composition-of-matter claims build on other composition-of-matter claims previously granted by the US Patent and Trademark Office and expand the protection of the company’s TAC platform and therapeutic product candidates.

Clinical Trials and Regulatory Designation

AUSTIN, Texas & HAMILTON, Ontario–Triumvira Immunologics Inc. (Triumvira), a private, clinical-stage biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for its novel T-cell therapy product TAC01-CD19 in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) after at least 2 prior systemic therapies.

Paul Lammers, MD, MSc., President and CEO of Triumvira commented, “Obtaining FDA and Health Canada clearance of our first IND for this novel approach fulfills our goal to be a clinical stage biotechnology company and demonstrates our commitment to bringing this innovative treatment to patients. TAC01-CD19 will be tested at five leading lymphoma clinical study centers in the U.S. and Canada.”

About Triumvira Immunologics

Triumvira Immunologics, Inc. (“Triumvira”) is a clinical stage immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.